Literature DB >> 35059869

The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 signaling.

Fatemeh Safari1, Nasim Shafiee Nejad2, Azadeh Aghaei Nejad3.   

Abstract

SGK223 is a scaffolding protein involving in the oncogenic tyrosine kinase signaling. SGK223 was phosphorylated at Y411 by c-Src and in response to the Epidermal growth factor receptor (EGFR). Tyrosine phosphorylated SGK223 at Y411 enables to interact with CSK resulting up regulation of c-Src activity and promotion of the cell migration. Human amniotic mesenchymal stromal cells (hAMSCs) are a population of multipotent cells that it was considered to be as a potential platform in cancer therapy. Herein, we employed a co-culture system to clarify the effects of hAMSCs secretome through tyrosine phosphorylation of c-Src, SGK223, AKT activity, and JAK1/Stat3 signaling in Panc1 pancreatic cancer cells. By using the 0.4 μm pore sized transwell membranes, both cell lines were firstly co-cultured for 72 h. Next, c-Src activity (tyrosine phosphorylation levels at Y530 and Y416), tyrosine phosphorylation level of SGK223 (at Y411), AKT activity, and JAK1/Stat3 signaling in Panc1 cells after treatment with hAMSCs were evaluated. Our results showed that hAMSCs have the inhibitory effects on Panc1 pancreatic cancer cells invasion and it suggests that the suppression of c-Src activity, SGK223 expression, AKT activity, and JAK1/Stat3 signaling may be as critical targets in pancreatic cancer therapy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  AKT; JAK1/Stat3 signaling; Pancreatic cancer cells; SGK223; Stem cells

Mesh:

Substances:

Year:  2022        PMID: 35059869     DOI: 10.1007/s12032-022-01649-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  2 in total

Review 1.  Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.

Authors:  Kodappully Sivaraman Siveen; Sakshi Sikka; Rohit Surana; Xiaoyun Dai; Jingwen Zhang; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Biochim Biophys Acta       Date:  2014-01-02

Review 2.  New Strategies and In Vivo Monitoring Methods for Stem Cell-Based Anticancer Therapies.

Authors:  Ping Wang; Aitor Aguirre
Journal:  Stem Cells Int       Date:  2018-11-15       Impact factor: 5.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.